Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Aug;5(4):641-5.

Synthesis and characterization of a recombinant hirudin-albumin complex

Affiliations
  • PMID: 7841322

Synthesis and characterization of a recombinant hirudin-albumin complex

M D Phaneuf et al. Blood Coagul Fibrinolysis. 1994 Aug.

Abstract

The purpose of this investigation was to covalently bind recombinant hirudin (rHir) to albumin and compare alpha-thrombin inhibition by complexed rHir to rHir. rHir was radiolabelled with 125I and covalently bound to albumin using heterobifunctional cross-linking reagents. HPLC purification of the 125I-rHir-SMCC-albumin complex using gel filtration chromatography resulted in four elution peaks, with the main peak containing an average M(r) of 78 kDa. This peak fraction also contained 63% (+/- 1.4%) of the total protein and 49% (+/- 6.8%) of the 125I-rHir conjugated to albumin. Purification of unbound 125I-rHir from complex was confirmed by SDS gel electrophoresis and autoradiography. 125I-rHir inhibition of alpha-thrombin, measured by an assay utilizing the chromogenic tripeptide substrate H-D-Phe-Pip-Arg-pNA (S-2238), was observed to be non-competitive of linear mixed-type having a Ki of 1.61 pM and an alpha Ki of 1.09 pM. In contrast, complexed 125I-rHir was found to be a pure, non-competitive inhibitor having a Ki of 15.6 pM showing a ten-fold increase. These results demonstrate that covalently bound 125I-rHir still maintains potent alpha-thrombin affinity while losing minimal inhibitory capacity. Thus, successful modification of 125I-rHir serves as the foundation for future alternative applications for this potent inhibitor.

PubMed Disclaimer

Similar articles

Publication types

LinkOut - more resources